BlackRock Inc. grew its position in Tocagen (NASDAQ:TOCA) by 36.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,069,152 shares of the company’s stock after acquiring an additional 285,396 shares during the quarter. BlackRock Inc. owned about 0.05% of Tocagen worth $10,960,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in TOCA. State Street Corp purchased a new stake in shares of Tocagen in the second quarter valued at $1,083,000. California State Teachers Retirement System purchased a new stake in shares of Tocagen in the second quarter valued at $179,000. JPMorgan Chase & Co. raised its stake in shares of Tocagen by 52.9% in the third quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock valued at $7,886,000 after acquiring an additional 218,100 shares during the period. Pure Financial Advisors Inc. purchased a new stake in shares of Tocagen in the fourth quarter valued at $1,324,000. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Tocagen by 118.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 29,900 shares of the company’s stock valued at $307,000 after acquiring an additional 16,200 shares during the period. 32.63% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently weighed in on TOCA shares. Zacks Investment Research raised shares of Tocagen from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. BidaskClub raised shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Finally, ValuEngine raised shares of Tocagen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $21.50.
TOCA stock opened at $10.12 on Wednesday. The stock has a market capitalization of $207.28 and a P/E ratio of -3.80. Tocagen has a 12 month low of $8.60 and a 12 month high of $17.95. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.05.
Tocagen (NASDAQ:TOCA) last posted its quarterly earnings results on Thursday, March 8th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.02). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Tocagen had a negative return on equity of 145.76% and a negative net margin of 94,948.78%. equities research analysts expect that Tocagen will post -2.3 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Tocagen (TOCA) Stake Raised by BlackRock Inc.” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/25/tocagen-toca-stake-raised-by-blackrock-inc.html.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.